- Home
- SILO vs SNSE Comparison
SILO vs SNSE Comparison
Compare SILO & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- SNSE
- Stock Information
- Founded
- SILO 2010
- SNSE 2005
- Country
- SILO United States
- SNSE United States
- Employees
- SILO N/A
- SNSE N/A
- Industry
- SILO Apparel
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- SILO Consumer Discretionary
- SNSE Health Care
- Exchange
- SILO Nasdaq
- SNSE Nasdaq
- Market Cap
- SILO 8.8M
- SNSE 9.3M
- IPO Year
- SILO N/A
- SNSE 2021
- Fundamental
- Price
- SILO $1.17
- SNSE $0.36
- Analyst Decision
- SILO
- SNSE Strong Buy
- Analyst Count
- SILO 0
- SNSE 4
- Target Price
- SILO N/A
- SNSE $4.25
- AVG Volume (30 Days)
- SILO 92.8K
- SNSE 8.3M
- Earning Date
- SILO 05-12-2025
- SNSE 05-08-2025
- Dividend Yield
- SILO N/A
- SNSE N/A
- EPS Growth
- SILO N/A
- SNSE N/A
- EPS
- SILO N/A
- SNSE N/A
- Revenue
- SILO $72,102.00
- SNSE N/A
- Revenue This Year
- SILO $1.86
- SNSE N/A
- Revenue Next Year
- SILO N/A
- SNSE N/A
- P/E Ratio
- SILO N/A
- SNSE N/A
- Revenue Growth
- SILO N/A
- SNSE N/A
- 52 Week Low
- SILO $0.77
- SNSE $0.25
- 52 Week High
- SILO $4.50
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- SILO 47.25
- SNSE 45.69
- Support Level
- SILO $0.99
- SNSE $0.33
- Resistance Level
- SILO $1.19
- SNSE $0.39
- Average True Range (ATR)
- SILO 0.08
- SNSE 0.05
- MACD
- SILO 0.02
- SNSE 0.00
- Stochastic Oscillator
- SILO 75.00
- SNSE 44.11
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).